Zuckerberg appoints AstraZeneca’s Cornelia Bargmann
September 28, 2016Research and Development AstraZeneca, Facebook, Mark Zuckerberg, Priscilla Chan
Zuckerberg and Chan have committed $3 billion of their own money to setting up the health initiative that has an …
80% of Chinese clinical trials’ data fabricated
September 28, 2016Manufacturing and Production, Research and Development China, Fabrication, corruption, report
The government review of clinical trial practise involved 1,622 programs of new pharmaceutical drugs waiting upon government approval to begin …
Provisional NICE recommendation for Gilead’s Hepatitis C treatment
September 28, 2016Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …
Merck elects Isabel De Paoli as CSO
September 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Amgen’s Kyprolis disappoints in Phase III trial
September 27, 2016Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III
Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …
Kite Pharma flying high after promising Car-T trial
September 27, 2016Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma
Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …
Price-hiked EpiPen profits 66% higher than Mylan CEO claimed
September 27, 2016Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen
In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …
Sanofi secures $43 million government funding for zika vaccine development
September 27, 2016Manufacturing and Production, Research and Development BARDA, Sanofi, Zika
The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the …
Johnson & Johnson’s Stelara receives FDA approval
September 27, 2016Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara
The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …
Biogen closes in on bringing muscular atrophy preventing drug to market
September 26, 2016Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen
Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …
CPHI Worldwide: PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules
September 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPhI
Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …
Pfizer decides not to break up business
September 26, 2016Sales and Marketing Ian Read, Pfizer, United States, america
In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …
Australian pharmaceutical market to grow to be worth $25 billion by 2020
September 26, 2016Business Services, Sales and Marketing Australia, Australian Government
The Australian market, in 2016, is currently worth over $22.85 billion and is predicted to reach $25.2 billion by 2020, …
Sanofi and Regeneron’s atopic dermatitis drug secures FDA priority review
September 26, 2016Research and Development, Sales and Marketing
Regeneron and Sanofi have announced that the US Food and Drug Administration has granted priority review for the pair’s atopic …
Merck elects Isabel De Paoli as CSO
September 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment
German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …
Woodley Equipment Company to Attend ICSE Exhibition, Barcelona
September 26, 2016Clinical Trials Supplier, medical and laboratory equipment provider
Woodley Equipment is attending ICSE Exhibition taking place on 4th to 6th October 2016 at Fira de Barcelona Gran Via, Barcelona, Spain.
FDA gives the green light to the first Humira biosimilar
September 26, 2016Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira
Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …
NICE approval for restricted-use hypophosphatasia therapy
September 23, 2016Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …
Top ten stories in the pharmaceutical industry this week
September 23, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …
Alzheimer’s drug failure sends Lundbeck’s shares crashing
September 23, 2016Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings
Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
